151 related articles for article (PubMed ID: 32719743)
1. Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 Modulates Aggressiveness of Ewing Sarcoma by Regulating the CD164-CXCR4 Axis.
Mancarella C; Caldoni G; Ribolsi I; Parra A; Manara MC; Mercurio AM; Morrione A; Scotlandi K
Front Oncol; 2020; 10():994. PubMed ID: 32719743
[TBL] [Abstract][Full Text] [Related]
2. Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 is a Novel Post-Transcriptional Regulator of Ewing Sarcoma Malignancy.
Mancarella C; Pasello M; Ventura S; Grilli A; Calzolari L; Toracchio L; Lollini PL; Donati DM; Picci P; Ferrari S; Scotlandi K
Clin Cancer Res; 2018 Aug; 24(15):3704-3716. PubMed ID: 29703820
[No Abstract] [Full Text] [Related]
3. EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma.
Cidre-Aranaz F; Grünewald TG; Surdez D; García-García L; Carlos Lázaro J; Kirchner T; González-González L; Sastre A; García-Miguel P; López-Pérez SE; Monzón S; Delattre O; Alonso J
Oncogene; 2017 Feb; 36(6):766-776. PubMed ID: 27375017
[TBL] [Abstract][Full Text] [Related]
4. Polymorphic variants of
Martinelli M; Mancarella C; Scapoli L; Palmieri A; De Sanctis P; Ferrari C; Pasello M; Zucchini C; Scotlandi K
Front Oncol; 2022; 12():968884. PubMed ID: 36338681
[TBL] [Abstract][Full Text] [Related]
5. Extracellular vesicle-associated IGF2BP3 tunes Ewing sarcoma cell migration and affects PI3K/Akt pathway in neighboring cells.
Mancarella C; Giusti V; Caldoni G; Laginestra MA; Parra A; Toracchio L; Giordano G; Roncuzzi L; Piazzi M; Blalock W; Columbaro M; De Feo A; Scotlandi K
Cancer Gene Ther; 2023 Sep; 30(9):1285-1295. PubMed ID: 37353558
[TBL] [Abstract][Full Text] [Related]
6. The CXCR4-CXCL12 axis in Ewing sarcoma: promotion of tumor growth rather than metastatic disease.
Berghuis D; Schilham MW; Santos SJ; Savola S; Knowles HJ; Dirksen U; Schaefer KL; Vakkila J; Hogendoorn PC; Lankester AC
Clin Sarcoma Res; 2012 Dec; 2(1):24. PubMed ID: 23249693
[TBL] [Abstract][Full Text] [Related]
7. CXCL14, CXCR7 expression and CXCR4 splice variant ratio associate with survival and metastases in Ewing sarcoma patients.
Sand LG; Scotlandi K; Berghuis D; Snaar-Jagalska BE; Picci P; Schmidt T; Szuhai K; Hogendoorn PC
Eur J Cancer; 2015 Nov; 51(17):2624-33. PubMed ID: 26428435
[TBL] [Abstract][Full Text] [Related]
8. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
9. Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 Influences Sensitivity to Anti-IGF System Agents Through the Translational Regulation of
Mancarella C; Pasello M; Manara MC; Toracchio L; Sciandra EF; Picci P; Scotlandi K
Front Endocrinol (Lausanne); 2018; 9():178. PubMed ID: 29731738
[TBL] [Abstract][Full Text] [Related]
10. The orphan nuclear receptor DAX1 is up-regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors.
Mendiola M; Carrillo J; García E; Lalli E; Hernández T; de Alava E; Tirode F; Delattre O; García-Miguel P; López-Barea F; Pestaña A; Alonso J
Int J Cancer; 2006 Mar; 118(6):1381-9. PubMed ID: 16206264
[TBL] [Abstract][Full Text] [Related]
11. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3.
Prieur A; Tirode F; Cohen P; Delattre O
Mol Cell Biol; 2004 Aug; 24(16):7275-83. PubMed ID: 15282325
[TBL] [Abstract][Full Text] [Related]
12. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
[TBL] [Abstract][Full Text] [Related]
13. Activation of Wnt/β-Catenin in Ewing Sarcoma Cells Antagonizes EWS/ETS Function and Promotes Phenotypic Transition to More Metastatic Cell States.
Pedersen EA; Menon R; Bailey KM; Thomas DG; Van Noord RA; Tran J; Wang H; Qu PP; Hoering A; Fearon ER; Chugh R; Lawlor ER
Cancer Res; 2016 Sep; 76(17):5040-53. PubMed ID: 27364557
[TBL] [Abstract][Full Text] [Related]
14. Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus.
Harlow ML; Maloney N; Roland J; Guillen Navarro MJ; Easton MK; Kitchen-Goosen SM; Boguslawski EA; Madaj ZB; Johnson BK; Bowman MJ; D'Incalci M; Winn ME; Turner L; Hostetter G; Galmarini CM; Aviles PM; Grohar PJ
Cancer Res; 2016 Nov; 76(22):6657-6668. PubMed ID: 27697767
[TBL] [Abstract][Full Text] [Related]
15. Long noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis.
Marques Howarth M; Simpson D; Ngok SP; Nieves B; Chen R; Siprashvili Z; Vaka D; Breese MR; Crompton BD; Alexe G; Hawkins DS; Jacobson D; Brunner AL; West R; Mora J; Stegmaier K; Khavari P; Sweet-Cordero EA
J Clin Invest; 2014 Dec; 124(12):5275-90. PubMed ID: 25401475
[TBL] [Abstract][Full Text] [Related]
16. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.
Giorgi C; Boro A; Rechfeld F; Lopez-Garcia LA; Gierisch ME; Schäfer BW; Niggli FK
Oncotarget; 2015 Oct; 6(30):28895-910. PubMed ID: 26336820
[TBL] [Abstract][Full Text] [Related]
17. Super-enhancer-associated MEIS1 promotes transcriptional dysregulation in Ewing sarcoma in co-operation with EWS-FLI1.
Lin L; Huang M; Shi X; Mayakonda A; Hu K; Jiang YY; Guo X; Chen L; Pang B; Doan N; Said JW; Xie J; Gery S; Cheng X; Lin Z; Li J; Berman BP; Yin D; Lin DC; Koeffler HP
Nucleic Acids Res; 2019 Feb; 47(3):1255-1267. PubMed ID: 30496486
[TBL] [Abstract][Full Text] [Related]
18. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.
Stegmaier K; Wong JS; Ross KN; Chow KT; Peck D; Wright RD; Lessnick SL; Kung AL; Golub TR
PLoS Med; 2007 Apr; 4(4):e122. PubMed ID: 17425403
[TBL] [Abstract][Full Text] [Related]
19. MiR-708-5p is inversely associated with EWS/FLI1 Ewing sarcoma but does not represent a prognostic predictor.
Roberto GM; Vieira GM; Delsin LEA; Silva MO; Hakime RG; Engel EE; Scrideli CA; Tone LG; Brassesco MS
Cancer Genet; 2019 Jan; 230():21-27. PubMed ID: 30470587
[TBL] [Abstract][Full Text] [Related]
20. Fluorescent CXCR4 targeting peptide as alternative for antibody staining in Ewing sarcoma.
Sand LGL; Buckle T; van Leeuwen FWB; Corver WE; Kruisselbrink AB; Jochemsen AG; Hogendoorn PCW; Szuhai K
BMC Cancer; 2017 May; 17(1):383. PubMed ID: 28549419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
